CuraCell TX AB has appointed Thomas Jaecklin and Martin Forster to its board of directors, as the company advances development of cell-based therapies. Dr Jaecklin has 25 years of experience in academic medicine, biotech and pharma, playing a pivotal role in building Mirum Pharmaceutical’s success in a treatment for cholestatic liver disease and, as chief medical officer of NodThera, shaping clinical strategy and financing. He has an MD from the University of Geneva, Switzerland.
Prof Forster is a Professor of Cancer Medicine at University College London (UCL), UK, and a consultant medical oncologist at UCL Hospitals NHS Foundation Trust. He specialises in thoracic and head and neck cancers. Curacell is developing treatments for cold solid tumours using a proprietary process to extract, activate and expand T-cells and convert them into cytotoxic effector cells. Its lead candidate, CC-38, is being evaluated in a Phase 1/2a clinical trial.
Curacell announced the appointments on 22 April 2026.
Copyright 2026 Evernow Publishing Ltd.